The prognostic role of immunohistochemical chromogranin A expressionin prostate cancer patients is significantly modified by androgen-deprivation therapy

Prostate

Volumn 70, Issue 7, 2010, Pages 718-726

  Berruti, Alfredo ^a   Bollito, Enrico ^a   Cracco, Cecilia M ^a   Volante, Marco ^a   Ciccone, Giovannino ^b   Porpiglia, Francesco ^a   Papotti, Mauro ^a   Scarpa, Roberto Mario ^a   Dogliotti, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Androgen deprivation therapy; Neuroendocrine differentiation; Prognosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHROMOGRANIN A; GONADORELIN DERIVATIVE;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL COUNT; CHI-SQUARE DISTRIBUTION; CHROMOGRANIN A; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77951845614     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21104     Document Type: Article

References (30)

1. Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Gatta G, Capocaccia R, Valdagni R, De Angelis R. Regional estimates of prostate cancer burden in Italy. Tumori 2007;93:380-386. (Pubitemid 47403454)
2. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-8151.
3. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61(2 suppl 1):14-24.
4. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771. (Pubitemid 28259189)
5. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352-3359.
6. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10(12 Pt 1):3943-3953. (Pubitemid 38812467)
7. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005;47:147-155. (Pubitemid 40126970)
8. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-687. (Pubitemid 26240320)
9. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-2119. (Pubitemid 27506024)
10. Sciarra A, Gentile V, Autran Gomez AM, Salciccia S, Gentilucci A, Monti S, Toscano V, Di Silverio F. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Endocr Relat Cancer 2007;14:625-632. (Pubitemid 350074052)
11. May M, Siegsmund M, Hammermann F, Loy V, Gunia S. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007;41:375-381. (Pubitemid 350034696)
12. Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D' Armiento M, De Placido S, Conti P, Di Lorenzo G. Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. Int J Immunopathol Pharmacol 2007;20:765-770.
13. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000;56:1011-1015.
14. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. BJU Int 1997;80:287-290. (Pubitemid 28318898)
15. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, van Weerden WM, Oomen MH, Schroder FH. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
16. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ. Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441. (Pubitemid 26145136)
17. Abrahamsson PA, Cockett ATK, di Sant'Agnese PA. Prognostic significance of neuroendocrine differentiation in clinical localized prostatic adenocarcinoma. Prostate Suppl 1998;8: 37-42. (Pubitemid 28347994)
18. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002;168:1204-1211.
19. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW. Long-term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 2008;68:1806-1815.
20. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007;27(5B):3651-3660. (Pubitemid 47607515)
21. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50:203-215. (Pubitemid 34184659)
22. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55:168-179. (Pubitemid 36532395)
23. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM, Dogliotti L. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J Urol 2007;178: 838-843. (Pubitemid 47211059)
24. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-117. (Pubitemid 40477092)
25. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66: 386-391. (Pubitemid 41138103)
26. Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, Fasolis G. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215-221. (Pubitemid 40957091)
27. Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia F, Berruti A, Papotti M, Volante M. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol 2008;21:700-707. (Pubitemid 351744835)
28. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007;282:3571-3583. (Pubitemid 47084471)
29. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgensensitive LNCaP cells. Endocr Relat Cancer 2006;13:151-167.
30. Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, Casarez EV, Amorino GP, Parsons SJ. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663-3672. (Pubitemid 46762151)